The House approved legislation to allow terminally ill the “right to try” experimental drugs not yet approved by the FDA on a largely partisan vote, sending the bill to a supportive President Donald Trump.

Reuters reports HCA’s proposal would essentially reverse Envision’s 2016 merger with AmSurg. The rest of the $5.1 billion Envision would be taken over by KKR.

UnitedHealth said it costs an average of $9,400 annually to cover a low-income, subsidized enrollee on the marketplace with $7,000 of that cost falling on the federal government. For someone eligible for Medicaid thanks to the Affordable Care Act (ACA), the overall cost is $5,400—with $5,100 coming from federal funds.

Direct federal funding for abortions has been prohibited by Congress for decades, but conservative lawmakers have sought to deny all federal funding to groups like Planned Parenthood for having any involvement in abortion services.

Three sponsors of Medicare Part D plans—UnitedHealth Group, Humana and CVS Health—account for more than half the program’s total enrollment. If proposed mergers involving smaller players like Aetna, Express Scripts and Cigna move ahead, the market would become even more concentrated.

Vermont has become the first state to pass a law to allow prescription drugs to be imported from Canada, but the plan still has to be approved by HHS—a tall order considering HHS Secretary Alex Azar’s comments that pharmaceutical imports are a “gimmick” and may be unsafe.

Primary care physicians and non-physician practitioners have seen their compensation rise more rapidly than specialists, which the Medical Group Management Association (MGMA) said is evidence of the worsening shortage of primary care doctors.

Lori Reilly, executive vice president of the Pharmaceutical Research and Manufacturers of America (PhRMA), spoke at a panel hosted by the Alliance for Health Policy on May 15, saying the group had “serious concerns” with the plan.